Altucell advances human islet cell encapsulation therapy for type 1 diabetes

August 22, 2023 09:20 AM AEST | By EIN Presswire

Google News:

Altucell advances human islet cell encapsulation therapy for type 1 diabetes — Image source: Kalkine Media

Recent News

Lynas (ASX:LYC) Boosts Rare Earth Capabilities with First Terbium Oxid...

Boss Energy Hits Production Milestone at Honeymoon Mine, Solidifying P...

Karoon Energy Expands Footprint in Santos Basin with New Exploration B...

ASX200 Opens Lower as Iron Ore Dips; Energy and Uranium Stocks Buck th...

This treatment could potentially eradicate the need for insulin and immunosuppressants

Our dedication, combined with advanced technologies, fuels our hope to enact real change in the lives of those affected by autoimmune conditions, especially type 1 diabetes”

— Gary Harlem

NEW YORK, USA, August 21, 2023/EINPresswire.com/ -- Altucell Therapeutics is making monumental advancements in the realm of diabetes care. The company remains at the forefront of groundbreaking research and it is currently engaged in human pilot studies with encapsulated human pancreatic islet transplantation for patients affected by type 1 diabetes mellitus. Altucell utilizes its signature platform encapsulation technology (AltuCaps), with the goal of negating the need for immunosuppressants.

The company, using its cutting-edge encapsulation technology, AltuCaps, aims to replace traditional treatments and avoid the need for immunosuppressants. Additionally, they have a full pipeline of cell lines designed to address major diseases more effectively than current interventions.

This advancement is just one of many that Altucell has to offer. Born from the CEO's personal journey – after his son was diagnosed with type 1 diabetes – Altucell has swiftly transformed into a biotech titan, specializing in cell-based therapies. Their unwavering mission to provide cures for diabetes and other autoimmune conditions using next-generation cell-based biologics.

The company's commitment to revolutionizing healthcare is showcased in its extensive pipeline of cell lines, all designed to tackle major diseases more efficiently than existing interventions. As a testament to their innovation, Altucell is being recognized as a company on the rise, demonstrating a significant growth trend and recently received an attractive valuation report.

"Altucell is not merely a company; it embodies a movement towards a brighter, healthier future. Our dedication, combined with advanced technologies, fuels our hope to enact real change in the lives of those affected by autoimmune conditions, especially type 1 diabetes," remarked the CEO of Altucell Therapeutics.

About Altucell Therapeutics: Altucell Therapeutics, often hailed as "the company to watch," stands as a beacon in the biotech industry. Passionately dedicated to devising innovative treatments for diabetes and other autoimmune diseases, Altucell's roots trace back to personal experiences. Driven by the vision of a world without diabetes, Altucell consistently pushes boundaries, aiming to develop more effective interventions and cures.
WWW.altucell.com

gary Harlem
Altucell
+1 631-586-4940
[email protected]
Visit us on social media:
Twitter
LinkedIn
Instagram

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.